UBS published a research note stating that despite Q3 headwinds from monetary tightening and a slowdown in M&A, the biotech sector remains resilient with intact fundamentals. The broker maintains a constructive view, expecting further upside into late 2026 and 2027.
UBS sees biotech fundamentals as strong, with M&A and IPO activity signaling a healthy sector, and recommends focusing on quality names despite near-term rate concerns.
Free preview — more China A-share & HK research · About Us · Legal & Privacy